Skip to main content Skip to main navigation menu Skip to site footer
logo Mediterranean Journal of Hematology and Infectious Diseases

eISSN 2035-3006

  • Home
  • About the Journal
  • Editorial Board
  • Current
  • Archives
  • Announcements
  • Register
  • Login
  • Journal Statistics
  • Search
  • Contact
  • Announcements

Editor-in-Chief: Giuseppe Leone | Italy

2.3
Impact Factor 2025
3.2
CiteScore 2025
2.3
Impact Factor 2025
3.2
CiteScore 2025
Submit
an article
  1. Home /
  2. Search

Search

Advanced filters
Published After
Published Before

Search Results

##search.searchResults.foundPlural##
  • EFFICACY AND SAFETY OF THALIDOMIDE IN PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA: A SYSTEMATIC REVIEW, META-ANALYSIS AND GRADE EVALUATION

    Jialian Li, Ping Ji, Qinyue Zhong, Lin Dong, Hai Yi, Baiyu Chen, Xu Zhang, Tingting Duan
    e2026033
    2026-04-30
    https://doi.org/10.4084/MJHID.2026.033
    357
    PDF: 373
    Suppl. Files: 64
    HTML: 100
  • THALIDOMIDE AMELIORATES ERYTHROPOIESIS AND IRON HOMEOSTASIS IN TRANSFUSION-DEPENDENT β-THALASSEMIA Thalidomide ameliorates erythropoiesis and iron homeostasis

    Kun Yang, Jian Xiao
    e2024001
    2024-01-01
    https://doi.org/10.4084/MJHID.2024.001
    1511
    PDF: 1482
    PDF: 1054
    HTML: 233
  • THALIDOMIDE FOR PATIENTS WITH THALASSEMIA INTERMEDIA: A RETROSPECTIVE MULTICENTER CLINICAL STUDY

    Kun Yang, Yi Wu, Yali Zhou, Tianhong Zhou, Li Wang, Zhili Geng, Xiaolin Yin
    e2020021
    2020-04-27
    https://doi.org/10.4084/mjhid.2020.021
    2323
    PDF: 1299
    HTML: 419
  • UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

    Patrizia Tosi, Manuela Imola, Mianulli Anna Maria, Simona Tomassetti, Anna Merli, Annalia Molinari, Serena Mangianti, Marina Ratta, Alessandro Isidori, Giuseppe Visani
    e2012069
    2012-11-05
    https://doi.org/10.4084/mjhid.2012.069
    2631
    PDF: 773
    HTML: 1646
  • Thalidomide treatment for thrombocytopenia secondary to hypersplenism in children with β-thalassemia major: a case series Thalidomide treatment for thrombocytopenia

    Kun Yang
    e2025037
    2025-04-30
    https://doi.org/10.4084/MJHID.2025.037
    969
    PDF: 787
    HTML: 267
  • Effect of Immunoglobulin Therapy on the Rate of Infections in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation and or Treated with Immunomodulatory Agents

    Alhossain A. Khalafallah, Matthias Maiwald, Amanda Cox, Burns Denise, Gerald Bates, Terry Hannan, David Seaton, Bernadene Fernandopulle, Terry Brain
    e2010005
    2010-04-20
    https://doi.org/10.4084/mjhid.2010.005
    1222
    PDF: 594
    HTML: 1195
  • EFFECTS OF THALIDOMIDE ON ENDOTHELIAL ACTIVATION AND STRESS INDEX IN CHILDREN WITH Β-THALASSEMIA MAJOR

    Kun Yang
    e2024076
    2024-10-31
    https://doi.org/10.4084/MJHID.2024.076
    1137
    PDF: 635
    HTML: 163
  • THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT

    Paul Richardson, Jacob Laubach, Anuj Mahindra, Constantine Mitsiades, Robert Schlossman, Irene Ghobrial, Teru Hideshima, Noopur Raje, Nikhil Munshi, Kenneth Anderson
    e2010009
    2010-05-03
    https://doi.org/10.4084/mjhid.2010.009
    1939
    PDF: 769
    HTML: 671
  • POEMS SYNDROME: AN UPDATE

    Andrea Nozza
    e2017051
    2017-09-01
    https://doi.org/10.4084/mjhid.2017.051
    3472
    PDF: 1716
    HTML: 1782
  • LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE

    Patrizia Tosi
    e2013037
    2013-06-03
    https://doi.org/10.4084/mjhid.2013.037
    1409
    PDF: 947
    HTML: 1301
    fig 1A: 215
    figure1B: 184
  • "ROLE OF ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA IN THE ERA OF NEW DRUGS"

    Benedetto Bruno, Luisa Giaccone, Moreno Festuccia, Mario Boccadoro
    e2010013
    2010-06-01
    https://doi.org/10.4084/mjhid.2010.013
    1547
    PDF: 694
    HTML: 1591
  • REAL WORLD MULTIPLE MYELOMA REGISTRY FROM JORDAN, A DEVELOPING COUNTRY.

    Abdalla Awidi, Farah Qasem, A'sem Abu-Qamar, Batool Aqel, Rand Aladayleh, Ilham Alteerah, Ahmad Magableh, , Hisham Bawa”neh, Feras Al-fararjeh
    e2022031
    2022-04-28
    https://doi.org/10.4084/MJHID.2022.031
    1413
    PDF: 808
    HTML: 419
  • Guest Editor: Pellegrino Musto HOW FIRST LINE THERAPY IS CHANGING IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS

    Yasmine Houbaida, Maria Livia Del Giudice, Sara Galimberti, Gabriele Buda
    e2025026
    2025-02-27
    https://doi.org/10.4084/MJHID.2025.026
    2101
    PDF: 1746
    HTML: 409
  • ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING

    Masafumi Taniwaki, Mihoko Yoshida, Yosuke Matsumoto, Kazuho Shimura, Junya Kuroda, Hiroto Kaneko
    e2018014
    2018-02-15
    https://doi.org/10.4084/mjhid.2018.014
    5410
    PDF: 2006
    HTML: 2115
  • COMPREHENSIVE REVIEW OF GENETIC AND EPIGENETICS REGULATION OF FETAL HEMOGLOBIN IN β-HEMOGLOBINOPATHIES: FROM MOLECULAR MECHANISMS TO CLINICAL APPLICATIONS HbF Genetics in Anemia

    Yousef Saeed Mohammad Abu Za’ror, Joseph Bagi Suleiman, Fatima Azzahra Delmani, Jehad Farouq Alhmoud, Amer Mohammad Ayasreh, Sarah Ihsan Al-wendawi, Maryam Azlan
    e2026046
    2026-04-30
    https://doi.org/10.4084/MJHID.2026.046
    933
    PDF: 661
    HTML: 113
  • FEASIBILITY AND OUTCOME OF FIRST-LINE AUTOTRANSPLANT-BASED TREATMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS AGED > 65 YEARS: MONOCENTRIC RETROSPECTIVE REAL-WORLD ANALYSIS Outcomes of ASCT in NDMM elderly fit patients

    Paola Stefanoni, Monica Galli, Laura Paris, Alessandro Rambaldi, Nicola Pittalis, Gianluca Cavallaro, Chiara Pavoni
    e2024066
    2024-08-31
    https://doi.org/10.4084/MJHID.2024.066
    1111
    PDF: 660
    Html: 178
  • EARLY APPLICATION OF HIGH CUT-OFF HAEMODYALISIS FOR DE-NOVO MYELOMA NEPHROPATHY IS ASSOCIATED WITH LONG-TERM DIALYSIS-INDEPENDENCY AND RENAL RECOVERY

    Alhossain A. Khalafallah, Sie Wuong Loi, Sarah Love, Muhajir B. Mohamed, Rose Mace, Ramy Khalil, Miriam Girgs, Rajesh Raj, Mathew Mathew
    e2013007
    2013-01-02
    https://doi.org/10.4084/mjhid.2013.007
    1452
    PDF: 694
    HTML: 2596
    cover letter: 228
  • Impact of daratumumab on stem cell mobilization and transplant in patient with newly diagnosed multiple myeloma: a real word single-center study

    Mauro Passucci, Francesca Fazio, Jacopo Micozzi, Manhaz Shafii Bafti, Giovanni Manfredi Assanto, Alfonso Piciocchi, Maurizio Martelli, Maria Teresa Petrucci
    e2024041
    2024-04-30
    https://doi.org/10.4084/MJHID.2024.041
    1320
    PDF: 1098
    Suppl. Files: 732
    HTML: 88
  • LIGHT CHAIN AMYLOIDOSIS

    Paolo Milani, Giampaolo Merlini, Giovanni Palladini
    e2018022
    2018-03-01
    https://doi.org/10.4084/mjhid.2018.022
    6199
    PDF: 2424
    HTML: 1560
  • IMPACT OF PRETRANSPLANT DONOR AND RECIPIENT CYTOMEGALOVIRUS SEROSTATUS ON OUTCOME FOR MULTIPLE MYELOMA PATIENTS UNDERGOING REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION.

    Jean Elcheikh
    e2013026
    2013-04-10
    https://doi.org/10.4084/mjhid.2013.026
    1373
    PDF: 773
    HTML: 1486
  • THE DARK SIDE OF THE COVID-19 TREATMENTS ON MYCOBACTERIUM TUBERCULOSIS INFECTION

    Flavio De Maio, Delia Mercedes Bianco, Giovanni Delogu
    e2022021
    2022-02-27
    https://doi.org/10.4084/MJHID.2022.021
    1390
    PDF: 805
    HTML: 324
  • Common variable immunodeficiency due to a novel NFKB1 variant in a child with thalassemia major CVID with thalassemia major

    Kun Yang
    e2023053
    2023-08-29
    https://doi.org/10.4084/MJHID.2023.053
    802
    PDF: 609
    HTML: 196
  • VON WILLEBRAND FACTOR, ANGIODYSPLASIA AND ANGIOGENESIS

    Anna M. Randi, Mike A Laffan, Richard D. Starke
    e2013060
    2013-09-02
    https://doi.org/10.4084/mjhid.2013.060
    3902
    PDF: 1648
    HTML: 8240
    Randi Fig: 209
  • THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA

    Xenofon Papanikolaou, Bart Barlogie, Saad Usmani
    e2011047
    2011-10-24
    https://doi.org/10.4084/mjhid.2011.047
    2580
    PDF: 827
    HTML: 1748
  • EFFECTS OF DARATUMUMAB ON HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA WHO ARE PLANNED TO RECEIVE AUTOLOGOUS TRANSPLANTATION: WHAT’S THE RELEVANCE?

    Pellegrino Musto, Dr. Nicola Sgherza
    e2024073
    2024-08-31
    https://doi.org/10.4084/MJHID.2024.073
    1641
    PDF: 874
    HTML: 228
  • WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE

    Maddalena Mazzucchelli, Anna Maria Frustaci, Marina Deodato, Roberto Cairoli, Alessandra Tedeschi
    e2018004
    2018-01-01
    https://doi.org/10.4084/mjhid.2018.004
    7889
    PDF: 2498
    HTML: 2122
    Table 1.: 255
    Table 2.: 262
    Table 3.: 243
    Table 4.: 239
  • Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analy

    Gianluca Cavallaro
    e2024049
    2024-04-30
    https://doi.org/10.4084/MJHID.2024.049
    2294
    HTML: 154
    PDF: 1191
  • Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis

    Fabiana Gentilini, Anna Levi, Vincenzo Federico, Eleonora Russo, Robin Foà, Maria Teresa Petrucci
    e2012035
    2012-05-07
    https://doi.org/10.4084/mjhid.2012.035
    1666
    PDF: 792
    HTML: 666
  • A case of fatal hyperammonaemic encephalopathy in a patient with end-stage Multiple Myeloma treated with daratumumab

    Mauro Passucci, Francesca Fazio, Maria Teresa Petrucci
    e2023012
    2023-01-01
    https://doi.org/10.4084/MJHID.2023.012
    1085
    PDF: 996
    HTML: 424
  • Guest Editor: Pellegrino Musto HOW FIRST-LINE THERAPY IS CHANGING IN NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS.

    Daniele Derudas
    e2025025
    2025-02-27
    https://doi.org/10.4084/MJHID.2025.025
    1714
    PDF: 1447
    HTML: 177
  • THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition

    Emiliano Fabiani, Dr. Falconi, Dr. Cristiano, Dr. Hajrullaj, Dr. Falconi, Prof. Leone, Prof. Voso
    e2023064
    2023-10-30
    https://doi.org/10.4084/MJHID.2023.064
    1508
    PDF: 975
    HTML: 258
  • Addition of daratumumab to first-line therapy of newly diagnosed multiple myeloma in patients eligible for autologous stem cell transplantation: a single-center real-life experience

    Edoardo Olivari
    e2025040
    2025-04-30
    https://doi.org/10.4084/MJHID.2025.040
    1157
    PDF: 816
    HTML: 203
  • RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM

    Ugo Testa, Elvira Pelosi, Germana Castelli, Giuseppe Leone
    e2023062
    2024-06-29
    https://doi.org/10.4084/MJHID.2024.062
    1374
    PDF: 1129
    HTML: 260
  • APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

    Tadeusz Robak
    e2010011
    2010-05-07
    https://doi.org/10.4084/mjhid.2010.011
    1725
    PDF: 678
    HTML: 2446
  • Brain abscesses caused by Nocardia paucivorans in a multiple myeloma patient treated with lenalidomide and dexamethasone: a case report and review of literature.

    Jacopo Monticelli, Roberto Luzzati, Cristina Maurel, Chiara Rosin, Romina Valentinotti, Claudio Farina
    e2015011
    2014-12-24
    https://doi.org/10.4084/mjhid.2015.011
    1765
    PDF: 1116
    HTML: 6563
    original file with images: 315
  • REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy

    Ulrike Bacher, Simon Brechbühl, Barbara Jeker, Thomas Pabst
    e2021012
    2021-01-01
    https://doi.org/10.4084/mjhid.2021.012
    1693
    PDF: 699
    HTML: 1450
  • TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS

    Eleonora De Bellis, Luana Fianchi, Francesco Buccisano, Marianna Criscuolo, Luca Maurillo, Laura Cicconi, Mattia Brescini, Maria Ilaria Del Principe, Ambra Di Veroli, Adriano Venditti, Francesco Lo-Coco, Maria Teresa Voso
    e2017045
    2017-07-01
    https://doi.org/10.4084/mjhid.2017.045
    4488
    PDF: 1804
    HTML: 1125
  • The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

    Michele Bibas
    e2024015
    2024-02-29
    https://doi.org/10.4084/MJHID.2024.015
    2492
    PDF: 1792
    HTML: 1015
  • Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET

    Alessandro Gozzetti, Vania Rossi, Alfonso Cerase, Giulia Papini, Marzia Defina, Monica Bocchia
    e2012041
    2012-06-19
    https://doi.org/10.4084/mjhid.2012.041
    1178
    PDF: 787
    HTML: 766
  • INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS IN THE ERA OF TARGET DRUGS

    Livio Pagano, Davide Facchinelli, Dr.
    e2018063
    2018-10-27
    https://doi.org/10.4084/mjhid.2018.063
    2156
    PDF: 1160
    HTML: 352
  • CYTOMEGALOVIRUS REACTIVATION IN ADULT RECIPIENTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

    omar ziad alrawi, fawzi abdel-latif abdel-rahman, rula alnajjar, husam abujazar, mourad salam, mustafa saad
    e2015049
    2015-08-25
    https://doi.org/10.4084/mjhid.2015.049
    1598
    PDF: 937
    HTML: 1022
    figures: 218
    table 1: 216
    table2: 214
    table3: 220
  • ClinicaI Reversible Myelopathy in T-Cell Lymphoblastic Lymphoma Treated with Nelarabine and Radiotherapy: Report of a Case and Review of Literature of an Increasing Complication

    Maria Chiara Tisi, Giuseppe Ausoni, Maria Gabriella Vita, Tommaso Tartaglione, Mario Balducci, Luca Laurenti, Patrizia Chiusolo, Stefan Hohaus, Simona Sica
    e2015025
    2015-02-17
    https://doi.org/10.4084/mjhid.2015.025
    2469
    PDF: 1043
    HTML: 1667
    Fig 1: 218
    Tab I: 242
    Cover Letter: 241
  • REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA

    Giovanni D'arena, Giovanni Rossi, Barbara Vannata, Silvia Deaglio
    e2012053
    2012-08-09
    https://doi.org/10.4084/mjhid.2012.053
    2411
    PDF: 1048
    HTML: 7699
    Untitled: 306
    Fig2: 212
    Fig3: 200
    Fig4: 215
  • QUALITY OF LIFE ASSESSMENT IN MULTIPLE MYELOMA PATIENTS UNDERGOING DOSE-REDUCED TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION

    Alhossain A. Khalafallah, Kristina McDonnell, Hizb U. Dawar, Iain Robertson, David Woods
    e2011057
    2011-11-28
    https://doi.org/10.4084/mjhid.2011.057
    1463
    PDF: 730
    HTML: 1389
    cover letter: 234
  • Efficacy and safety of teclistamab followed by autologous stem cells transplant in functional high-risk and triple class refractory multiple myeloma

    Vincenzo Sammartano, Sara Ciofini, Beatrice Esposito Vangone, Chiara Carrara, Monica Bocchia, Alessandro Gozzetti
    e2025051
    2025-06-29
    https://doi.org/10.4084/MJHID.2025.051
    819
    PDF: 631
    HTML: 58
  • Guest Edtor: Pellegrino Musto NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES

    Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia, Antonella Poloni, Massimo Offidani
    e2025027
    2025-02-27
    https://doi.org/10.4084/MJHID.2025.027
    1539
    PDF: 1320
    HTML: 438
  • PROGNOSTIC IMPACT OF NEUROPILIN-1 EXPRESSION IN EGYPTIAN CHILDREN WITH B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA

    adel abd elhaleim hagag, Nahla A Nosair
    e2015009
    2014-12-28
    https://doi.org/10.4084/mjhid.2015.009
    1707
    PDF: 867
    HTML: 2164
  • Measurement of erythrocyte lifespan using a CO breath test in patients with thalassemia and the impact of treatment erythrocyte lifespan in patients with thalassemia

    xiaolin yin, Jingting Luo
    e2023050
    2023-08-29
    https://doi.org/10.4084/MJHID.2023.050
    858
    PDF: 597
    HTML: 211
  • Guest Editor: Pellegrino Musto AN UPDATE OF THE APPROPRIATE SEQUENCING FOR SALVAGE THERAPIES IN MULTIPLE MYELOMA

    Gregorio Barila', Francesca Rezzonico, Laura Pavan, Alessandro Corso, Renato Zambello
    e2025043
    2025-04-30
    https://doi.org/10.4084/MJHID.2025.043
    1266
    PDF: 1014
    HTML: 298
  • EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES

    Pietro Tralongo, Arianna Bakacs, Luigi Maria Larocca
    e2024042
    2024-04-30
    https://doi.org/10.4084/MJHID.2024.042
    4639
    PDF: 1798
    HTML: 1252
1 - 50 of 63 items 1 2 > >> 
Make a Submission

Links

  • Editorial Board
  • Alert me!
  • Advertising
  • Scopus
  • DOAJ
  • Article Processing Charge

Information

  • For Readers
  • For Authors
  • For Librarians

Indexing

  • OpenAlex
  • Analytics

PubMed

MJHID CiteScore by Scopus

Clarivate Analytics

this journal is covered
by Clarivate Analytics

 

The Mediterranean Journal of Hematology and Infectious Diseases has been selected for coverage in Clarivate Analytics products and services. Beginning with V. 7 (1) 2015.

AskBisht

Indexed in AskBisht.com

Facebook

FOLLOW US

MJHID in EuroPub Database

EuroPub

CLL UpDate

Keywords

Mediterranean Journal of Hematology and Infectious Diseases

is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. The MJHID is indexed and abstracted in Science Citation Index Expanded and Journal Citation Reports/InCites beginning with V. 7 (1) 2015.

eISSN: 2035-3006

Info

  • About
  • Editorial Board
  • News
  • Advertising

Info Submission

  • Submission

Our App Is Free For Anyone!

© PAGEPress 2008-2026    •    PAGEPress® is a registered trademark property of PAGEPress srl, Italy    •    VAT: IT02125780185
This journal is published by PAGEPress® srl (Pavia, Italy), which is the data controller for all personal data processed through this platform. For full details on how your data is collected, used and protected, please read our Privacy Policy.